National Healthcare Properties, Inc. (NHP) stock
NHPNASDAQReal EstateISIN US42226B6002
40Score 40 out of 100, Weak
Price and trend
79 / 100
Price history
+26% since 2026The chart shows daily closing prices since 22 Apr 2026, adjusted for stock splits and excluding dividends. Click into the chart to set a price alert at that price.
Normal: the price is neither overheated nor sold off (RSI 46).
The price is 11% below its 52-week high. Largest decline since 22 Apr 2026: 14% (August 2026 to October 2026).
Chart figures for advanced users
- SMA 50$15.65
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$15.17
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)46
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$12.00
- The lowest closing price of the last twelve months.
- Resistance$17.08
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- National Healthcare Properties, Inc. (NHP) belongs to the REIT (Healthcare Facilities) industry (United States) and, with a market value of $1.11B, is number 13 of 18 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $342.28M (down 3.3% year on year) and a loss of $57.62M.
- For fiscal 2026, analysts expect on average revenue of $369.55M (up 8%) and adjusted earnings per share of $0.79.
Show more
- MEQIRI Score 40 out of 100 (Weak): rank 291 of 325 in Real Estate, median 55.
- For real estate investment trusts (REITs) what counts is funds from operations (FFO and AFFO). The P/E and the payout ratio of earnings say little here, because depreciation on properties depresses earnings.
- Our model puts fair value at $9.57, with the price 59% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- Interest barely coveredOperating profit covers interest only 0.1 times.Stability 54
- Loss-makingLoss of $18.26M over the last 12 months.Fundamentals 18
- Above fair valuePrice 59% above the fair value of $9.57.Valuation 34
Its standout strength is technical analysis, while fundamentals and profitability hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 41 to 40.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
Significantly overvaluedIn our model the price counts as cheap below $7.36 and expensive above $13.67 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $10.44 (cash-flow model) and $8.70 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $8.68, at 7.8% it would be $10.90.
Valuation metrics
Half from the cash-flow model, half from FFO per share times the median price to FFO of the REIT industry (16.6). For REITs, depreciation on buildings depresses earnings, so FFO counts instead of earnings, here following the industry rule (Nareit) from the filings with the SEC: gains on property sales are deducted where the company reports them in the standard items. The cash-flow model uses AFFO: operating cash flow less maintenance, estimated at 4% of revenue, and less preferred dividends. New construction and acquisitions do not count as running costs there.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 4.6% on the twelve months before. Revenue has stayed largely stable since 2022.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 36%, operating 1%, net −17%. Last 12 months: net −5%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 4 Dec 2026in 21 days
- Last reported
- 4 Nov 2026EPS reported $0.24 (expected $0.85)below expectations
Analyst estimates
- Earnings per share
- $0.79+51.0%
- Revenue
- $369.55M+2.7%
- Earnings per share
- $0.39+441.7%
- Revenue
- $421.68M+8.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at National Healthcare Properties, Inc. (NHP)
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
325 rated companies in Real Estate
- This company
- 40
- Sector median
- 55
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in REIT (Healthcare Facilities)
The next larger and next smaller companies by market value
- Sabra Health Care REITSBRA $5.39B50
- National Health InvestorsNHI $3.17B60
- LTC PropertiesLTC $2.46B71
- Diversified Healthcare TrustDHC $1.77B32
- Medical Properties TrustMPT $1.02B40
- Care Property InvestCPINV.BR $599.59M65
- Universal Health Realty Income TrustUHT $537.64M61
- Community Healthcare TrustCHCT $423.04M56
ETFs that hold National Healthcare Properties, Inc. (NHP)
Held by 2 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.02% | 0.30% | €4.28B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.22B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 15 Oct 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.